Posters

N 1 - 30

N.1

Poster

Tenofovir Alafenamide improves proximal tubular markers in CHB patients long‐term treated with Tenofovir Disoproxil Fumarate: a real‐life study based on the EASL switching criteria

A. Loglio, M. Viganò, M. Borghi, C. Gentile, F. Facchetti, D. Sambarino, R. Perbellini, R. Soffredini, S.C. Uceda Renteria, M.G. Rumi, P. Lampertico – Milan

Poster

N.2

Poster

Non‐invasive tests to predict liver‐related events in a single‐center cohort of 486 HCV cirrhotic patients treated with DAA

E. Degasperi, R. D’Ambrosio, I. Fanetti, R. Perbellini, M.P. Anolli, M. Borghi, R. Soffredini, P. Lampertico Milan

Poster

N.3

Poster

Incidence of liver‐related events in 647 HCV cirrhotics treated with DAA: a 5‐year single center study

R. D’Ambrosio, E. Degasperi, M.P. Anolli, I. Fanetti, M. Borghi, R. Soffredini, M. Iavarone, G. Tosetti, R. Perbellini, A. Sangiovanni, P. Lampertico – Milan

Poster

N.4

Poster

Coagulation balance and liver damage in non‐cirrhotic patients with chronic hepatitis C after eradication by Direct‐acting Antiviral Agents (DAAs)

G. Sigon, R. D’Ambrosio, M.G. Clerici, G. Pisano, V. Chantarangkul, R. Sollazzi, A. Cespiati, F. Iuculano, R. Lombardi, F. Peyvandi, P. Lampertico, S. Fargion, A. Tripodi, A.L. Fracanzani – Milan

Poster

N.5

Poster

New onset steatosis but not persistent steatosis prevents hepatic fibrosis improvement after viral eradication by direct‐acting antiviral therapy (DAAs) in patients with chronic hepatitis C: evaluation by controlled attenuation parameter (CAP) and liver stiffness measurement LSM

A. Cespiati, S. Petta, R. Lombardi, V. Di Marco, V. Calvaruso, C. Bertelli, G. Pisano, E. Fatta, G. Sigon, F. Iuculano, L. Crapanzano, G. Gibilaro, P. Francione, A. Craxì, S. Fargion, A.L. Fracanzani ‐ Milan, Palermo

Poster

N.6

Poster

The “CASERTA MODEL”: Caserta HCV Free Hospital

V. Messina, A. Petruzziello, E. Tripaldelli, T. Squeglia, A. del Prete, P. Maggi, N. Coppola ‐ Caserta, Naples

Poster

N.7

Poster

Excellent long‐term virological and clinical response in HDV compensated cirrhotics treated with high dose Bulevirtide beyond 2.5 years: a case series

A. Loglio, P. Ferenci, S.C. Uceda Renteria, H. Holzmann, M. Borghi, R. Perbellini, A. Rimondi, E. Trombetta, S. Giovanelli, L. Porretti, D. Prati, F. Ceriotti, P. Lampertico ‐ Milan, Vienna (Austria)

Poster

N.8

Poster

A new model of care involving General Practitioners for HCV elimination in patients with mild liver disease: the experience of Pordenone (Friuli Venezia Giulia)

E. Garlatti Costa, G. Marcassa, G. Lucchini, A. Berto, R. De Rosa, M. Tonizzo – Pordenone

Poster

N.9

Poster

A multimedia multilanguage web‐based platform can assess and increase the awareness on HCV infection of Pakistani people living in Italy

L. Frazzoni, U. Sikandar, G. Mazzella, L. Fuccio, F. Bazzoli, S. Brillanti, F. Azzaroli ‐ Bologna, Siena

Poster

N.10

Poster

Long‐term efficacy and safety of obeticholic acid in patients with PBC from the POISE trial grouped biochemically by risk of disease progression

C. L. Bowlus, M. Trauner, A. Liberman, E. Malecha, L. MacConell, A.E. Kremer, F. Nevens, A. Floreani ‐ Sacramento (CA, USA), Vienna (Austria), San Diego (CA, USA), Erlangen (Germany), Leuven (Belgium), Padua

Poster

N.11

Poster

Epidemiological and clinical profile of 302 patients with primary biliary cholangitis in Piedmont and Liguria

C. De Benedittis, S. Labanca, A. Picciotto, A. Morgando, E. Vanni, D. Azzolina, M.G. Cittone, M. Pirisi, C. Rigamonti ‐ Novara, Genua, Turin

Poster

N.12

Poster

Pattern of progression of intrahepatic cholangiocarcinoma impacts on survival: implications for second‐line trials

F. Tovoli, I. Garajovà, M. Iavarone, P. Federico, F. Gelsomino, A. Granito, B. Daniele, A. Forgione, F. Piscaglia ‐ Bologna, Parma, Milan, Naples, Modena

Poster

N.13

Poster

Metabolic reprogramming and mitochondrial dysfunction in HepG2 cells as potential drivers of AIP pathophysiology

M. Longo, M. Meroni, E. Paolini, M.D. Cappellini, I. Motta, A.L. Fracanzani, E. Di Pierro, P. Dongiovanni Milan

Poster

N.14

Poster

Whole exome sequencing for the diagnosis of rare genetic conditions in patients with unexplained liver disease and complex clinical presentation

S. Pelusi, F. Malvestiti, G. Baselli, C. Bianco, C. Santaniello, L. Santoro, G. Soardo, R. D’Ambrosio, W. Barcellini, M. Miozzo, D. Prati, L. Valenti ‐ Milan, Udine

Poster

N.15

Poster

EILF‐Italian migrants study: an HCV and HBV micro elimination pilot project

G. Colucci, S. Uceda Renteria, G. Lunghi, F. Ceriotti, E. Sguazzini, S. Spalenza, C. Regazzo, S. Scotti, E. Renesto, A. Zucchetti, C. Paratore, P. Lampertico, M. Colombo ‐ Milan, Geneve (Switzerland)

Poster

N.16

Poster

Hepatocellular liver injury in hospitalized patients affected by COVID‐19: different factors at different time points

M. Leo, A. Galante, A. Pagnamenta, F.R. Ponziani, A. Gasbarrini, A. De Gottardi – Lugano (Switzerland), Rome, Bellinzona (Switzerland)

Poster

N.17

Poster

High prevalence of multiple drug resistant bacterial infections in patients with pyogenic liver abscesses following loco regional therapy for liver cancer

F. Colapietro, C. Masetti, N. Pugliese, I. Bianchi, D. Poretti, V. Pedicini, A. Lleo, R. Ceriani, A. Aghemo Rozzano (Milan), Pieve Emanuele (Milan)

Poster

N.18

Poster

The Fibrosis‐4 index is associated with Intensive Care Unit (ICU) admission in middle‐aged patients with COVID‐19

E. Biliotti, P. Piselli, U. Visco Comandini, R. Lionetti, C. Taibi, L. Vincenzi, S. Al Moghazi, A. Antinori, E. Caraffa, C. Cimaglia, L. Marchioni, A. Mariano, I. Mastrorosa, S. Mosti, A. Navarra, E. Nicastri, F. Palmieri, E. Girardi, G. D’Offizi and ReCOVeRI Study Group – Rome

Poster

N.19

Poster

High levels of transaminases at admission predict a severe disease course in COVID‐19 hospitalized patients

F. Pelizzaro, M.P. Kitenge, F. Maran, E. Cocconcelli, E. Balestro, P. Spagnolo, A. Cattelan, F. Farinati-Padua

Poster

N.20

Poster

Pilot screening of HBV and HCV prevalence in at risk populations due to geographical origin and conditions of socio‐economic distress

S. Lorini, L. Gragnani, S. Marri, F. Madia, M. Monti, C. Stasi, L. Petraccia, M. Bamoshmoosh, A.L. Zignego Florence, Sana’a (Yemen)

Poster

N.21

Poster

Correlation of the transaminases alteration with the clinical severity of patients with COVID‐ 19: a meta‐analysis of the first global outbreak

L. Miele, M. Dajko, G. Marrone, A. De Magistris, M. Biolato, A. Liguori, G.L. Rapaccini, G. Gasbarrini, A. Grieco – Rome

Poster

N.22

Poster

Eating habits in patients affected by metabolic syndrome and liver disease (hepatitis, cirrhosis and liver transplant)

L. Brodosi, D. Mita, G. Simonetti, G. Vitale, A. Gentile, M. Genovese, G. Marchesini, M.C. Morelli, L. Pironi – Bologna

Poster

N.23

Poster

Thrombocytopenia in chronic liver disease: the analysis of Italian administrative healthcare data by Fondazione RES

L. Dondi, G. Ronconi, S. Calabria, C. Piccinni, A. Pedrini, I. Esposito, N. Caporaso, U. Vespasiani Gentilucci, A. Iacobellis, N. Martini ‐ Casalecchio di Reno (Bologna), Rome, Naples, San Giovanni Rotondo (Foggia)

Poster

N.24

Poster

A challenging case of chronic haemolisys in liver cirrhosis: spur cell anemia

M. Bevilacqua, G. Marchi, F. Dima, R. Stupia, V. Paon, D. Ieluzzi, A. Dalbeni, D. Girelli, D. Sacerdoti – Verona

Poster

N.25

Poster

Psychological profiles and risk of relapse in cirrhosis due to alcohol abuse

A. Galeota Lanza, G. Mazzarone, V.G.M. Moreas, A. Cangiano, F. Giordano, G. Aragiusto, G. Arenga, L. Campanella, A. Ceriello, D. Ferraro, C. Migliaccio, D. Pisaniello, I. Esposito, F. Picciotto, G. Di Costanzo, C. Chierego, C. Esposito, G. Vennarecci – Naples

Poster

N.26

Poster

NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease
S. Grimaudo, P. Dongiovanni, J. Pihlajamäki, M. Eslam, H. Yki‐Järvinen, R.M. Pipitone, G. Baselli, C. Cammà, V. Di Marco, M. Longo, G. Pennisi, D. Prati, R. Zito, A.L. Fracanzani, A. Craxì, J. George, S. Romeo, L. Valenti#, S. Petta# ‐ Palermo, Milan, Kuopio (Finland), Westmead (NSW, Australia), Helsinki (Finland), Gothenburg (Sweden)

Poster

N.27

Poster

The role of variant rs17618244 of KLB gene in MAFLD‐related fibrosis

N. Panera, M. Meroni, M. Longo, A. Crudele, L. Valenti, E. Bellacchio, L. Miele, V. D’Oria, E. Paolini, M. Maggioni, A.L. Fracanzani, A. Alisi, P. Dongiovanni ‐ Rome, Milan

Poster

N.28

Poster

Obeticholic acid demonstrates sustained improvements at month 24 in transaminases and non‐ invasive markers of fibrosis: results of a post hoc analysis from the interim analysis of the REGENERATE study

R. Loomba, V. Ratziu, Q. M. Anstee, S. Harrison, A.J. Sanyal, M. Rinella, Z. Y. Younossi, Z. Goodman, P. Bedossa, R. Shringarpure, H. Zhou, M. Noureddin, E. Bugianesi ‐ San Diego (CA, USA), Paris (France), Newcastle upon Tyne (United Kingdom), San Antonio (TX, USA), Richmond (VA, USA), Chicago (IL, USA), Falls Church (VA, USA), Los Angeles (CA, USA), Turin

Poster

N.29

Poster

Rare and common ATG7 variants predispose to severe fatty liver disease

G. Baselli, S. Pelusi, E. Ciociola, P. Dongiovanni, M. Maggioni, F. Tavaglione, C. Bianco, R.M. Mancina, L. Santoro, S. Petta, L. Miele, U. Vespasiani Gentilucci, A. Federico, E. Bugianesi, A.L. Fracanzani, H. Reeves, G. Soardo, M. Miozzo, EPIDEMIC study investigators, D. Prati, S. Romeo, L. Valenti ‐ Milan, Gothenburg (Sweden), Rome, Udine, Palermo, Naples, Turin, Newcastle upon Tyne (UK), Catanzaro

Poster

N.30

Poster

A cholestatic pattern predicts liver outcomes in patients with nonalcoholic fatty liver disease

G. Pennisi, R. M. Pipitone, S. Grimaudo, F. Spatola, V. Di Martino, C. Cammà, V. Di Marco, A. Craxì, S. Petta – Palermo

Poster

N 31 - 60

N.31

Poster

TM6SF2/PNPLA3/MBOAT7 loss‐of‐function genetic variants impact on NAFLD development and progression both in patients and in in vitro models

M. Longo, M. Meroni, V. Erconi, F. Carli, C. Macchi, D. Ronchi, S. Sabatini, E. Paolini, E.R. De Caro, A. Alisi, L. Miele, G. Soardo, G.P. Comi, L. Valenti, M. Ruscica, A.L. Fracanzani, A. Gastaldelli, P. Dongiovanni ‐ Milan, Pisa, Rome, Trieste

Poster

N.32

Poster

Increased serum ferritin levels predict long‐term mortality in patients with NAFLD

A. Armandi, R. Younes, G.P. Caviglia, S. Petta, L. Miele, C. Rosso, G. Pennisi, P. Francione, A. Liguori, O. Govaere, A.L. Fracanzani, M. Eslam, L. Valenti, J. George, Q.M. Anstee, E. Bugianesi ‐ Turin, Ingelheim (Germany), Palermo, Rome, Milan, Newcastle upon Tyne (United Kingdom), Westmead (NSW, Australia)

Poster

N.33

Poster

MicroCT evaluation of low‐density segmented volume in II, IV and VII‐week MCD rats

M. Filibian, L.G. Di Pasqua, C. Berardo, M. Cagna, M. Vairetti, A. Ferrigno – Pavia

Poster

N.34

Poster

Angiopoietin‐2 associated with NASH in paediatric NAFLD

N. Panera, M. Manco, A. Crudele, M.R. Braghini, M. Bianchi, D. Comparcola, R. De Vito, G. Maggiore, A. Alisi – Rome

Poster

N.35

Poster

The I148M PNPLA3 variant mitigates Niacin beneficial effects: how the genetic screening in NAFLD patients gains value

E. Paolini, M. Longo, M. Meroni, G. Malaspina, E.R. De Caro, A. Cespiati, R. Lombardi, A.L. Fracanzani, P. Dongiovanni – Milan

Poster

N.36

Poster

No impact of the 2020 COVID‐19 lockdown on hospitalization rates for alcoholic liver disease in a large tertiary hospital in Milan

C. Masetti, F. Colapietro, N. Pugliese, F. De Fazio, A. Voza, I Bianchi, R. Ceriani, A. Lleo, A. Aghemo ‐ Rozzano (Milan), Pieve Emanuele (Milan)

Poster

N.37

Poster

General Practitioner databaSe NAFLD (GPS‐NAFLD) study: Italian regional variability of the NAFLD prevalence rate

L. Miele, I. Grattagliano, F. Lapi, M. Dajko, A. Liguori, A. De Magistris, C. Napodano, A. Rossi, G. Rapaccini, A. Gasbarrini, C. Cricelli, A. Grieco – Rome, Florence

Poster

N.38

Poster

Oleuropein prevents liver damage in NAFL mice by modulating copper‐catalyzed dicarbonyl stress

S.J. Santini, I. Settepanella, C. Balsano ‐ L’Aquila, Rome

Poster

N.39

Poster

Screening and detecting significant liver fibrosis in patients with NAFLD: a practical approach using non‐invasive tests

G. Alterini, P. Sacco, C. Formichi, C. Ciuoli, E. Ceccarelli, S. Gonnelli, L. Volterrani, M.G. Castagna, F. Dotta, S. Brillanti – Siena

Poster

N.40

Poster

Multimorbidity and polypharmacotherapy in Italian primary care patients with NAFLD: General Practitioner databaSe NAFLD (GPS‐NAFLD) Study

L. Miele, C. Cricelli, F. Lapi, I. Grattagliano, M. Dajko, A. Liguori, A. De Magistris, C. Napodano, G. Marrone, M. Biolato, A. Rossi, G. Rapaccini, A. Grieco, A. Gasbarrini – Rome, Florence

Poster

N.41

Poster

The PSRC1 rs599839 A>G variant disentangles the risk of coronary artery disease and hepatocellular carcinoma in Italian NAFLD patients
M. Meroni, M. Longo, E. Paolini, E.R. De Caro, A. Alisi, L. Miele, G. Soardo, L. Valenti, A.L. Fracanzani, P. Dongiovanni ‐ Milan, Rome, Trieste

Poster

N.42

Poster

Prognostic role of platelets‐to lymphocytes ratio (PLR) and neutrophils‐to‐lymphocytes ratio (NLR) in hepatocellular carcinoma patients

F. Pelizzaro, A. Sartori, A. Imondi, B. Penzo, A. Vitale, F. Trevisani, F. Farinati on behalf of the Italian Liver Cancer (ITA.LI.CA) group – Padua, Bologna

Poster

N.43

Poster

Is first‐ and second‐line immunotherapy sequence the optimal strategy for unresectable hepatocellular carcinoma?

C. Celsa, G. Cabibbo, S. Battaglia, M. Enea, G.E.M. Rizzo, A. Busacca, C. Stornello, P. Giuffrida, A. Craxì, C. Cammà ‐ Palermo

Poster

N.44

Poster

The protease‐inhibitor serpinB3 as a critical modulator of the stem‐like subset in human cholangiocarcinoma

M. Correnti, A. Cappon, M. Pastore, B. Piombanti, G. Lori, D. VPN Oliveira, P. Munoz‐Garrido, M. Lewinska, J.B. Andersen, C. Coulouarn, L. Sulpice, G. Cavalloni, S. Quarta, A. Biasiolo, M. Fassan, P. Invernizzi, G. Torzilli, F. Marra, P. Pontisso, C. Raggi – Rozzano (Milan), Padua, Florence, Copenhagen (Denmark), Rennes (France), Turin, Monza

Poster

N.45

Poster

Perfusion analysis with dynamic contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma: a pilot study of a novel parameter aiming to improve the detection of wash‐out

L. Mulazzani, A. Forgione, C. Di Bonaventura, E. Terzi, L. Gramantieri, A. Lyshchik, F. Piscaglia ‐ Bologna, Philadelphia (PA, US)

Poster

N.46

Poster

Progression‐free survival is a robust surrogate endpoint of overall survival in immunotherapy trials of hepatocellular carcinoma

C. Celsa, G. Cabibbo, M. Enea, S. Battaglia, G.E.M. Rizzo, A. Busacca, D. Matranga, M. Attanasio, M. Reig, A. Craxì, C. Cammà ‐ Palermo, Barcelona (Spain)

Poster

N.47

Poster

Hepatocellular carcinoma prognostic scores: a 10 years experience

M. Campigotto, M. Giuffrè, A. Colombo, A. Visintin, M. Budel, A. Aversano, C.A.M. Cavalli, A. Piccin, R. Sigon, F. Masutti, C. Abazia, F. Tinè, L.S. Crocè – Trieste

Poster

N.48

Poster

Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma. A diagnostic test accuracy Cochrane review

A. Colli, T. Nadarevic, D. Miletic, V. Giljaca, M. Fraquelli, D. Štimac, G. Casazza ‐ Milan, Rijeka (Croatia), Birmingham (UK)

Poster

N.49

Poster

A mitochondrial role of RuvBL1 ATPase in the regulation of HCC cell metabolism

I. Simeone, A. Guida, M. Materozzi, S. Polvani, D. Bani, M. Parri, E. Ceni, A. Galli, T. Mello ‐ Florence, Siena

Poster

N.50

Poster

Fatty Acids regulate the biology of cholangiocarcinoma cells

G. Lori, C. Raggi, B. Piombanti, M. Pastore, R. Booijnk, E. Rovida, J.B. Andersen, M. Lewinska, F. Marra – Florence, Twente (The Netherlands), Copenhagen (Denmark)

Poster

N.51

Poster

AFP at transplant is associated with a higher risk of HCC recurrence after liver transplantation for patients meeting Milano criteria

B. Magro, D. Pinelli, M. De Giorgio, A. Ghirardi, B. Giuseppe, L. Del Prete, M. Colledan, S. Fagiuoli Bergamo

Poster

N.52

Poster

Increased platelet aggregation in patients with cirrhosis and hepatocellular carcinoma: a new potential therapeutic target?

A. Zanetto, E. Campello, S. Shalaby, M. Gambato, A. Vitale, U. Cillo, F. Farinati, F.P. Russo, P. Burra, P. Simioni, M. Senzolo – Padua

Poster

N.53

Poster

Circulating microRNA‐23b‐3p and tissue microRNA‐193a‐3p as promising molecular biomarkers in human hepatocellular carcinoma

I. Grossi, G. Baiocchi, S. Molfino, N. Portolani, M. Ferracin, P. Guerriero, M. Negrini, A. Salvi, G. De Petro Brescia, Bologna, Ferrara

Poster

N.54

Poster

Copper chelation as a new treatment strategy to counteract hepatocellular carcinoma

S.J. Santini, M.R. Braghini, A. Alisi, C. Balsano ‐ L’Aquila, Rome

Poster

N.55

Poster

Abnormal glycosphingolipid patterns in human cholangiocarcinoma stem‐like subsets

A. Mannini, C. Raggi, M. Correnti, E. Rovida, M. Aureli, E.V. Carsana, B. Piombanti, M. Pastore, J. Andersen, C. Coulouarn, F. Marra ‐ Milan, Florence, Copenhagen (Denmark), Rennes (France)

Poster

N.56

Poster

Modeling hepatocellular carcinoma cells dynamics by serological and imaging biomarkers in patients with response to sorafenib and/or regorafenib

P.Colombatto, C.O.Demirtas, G.Ricco, L.Civitano, P.Boraschi, P.Scalise, D.Cavallone, F.Oliveri, V. Romagnoli, P. Bleve, B. Coco, A. Salvati, L. Urbani, F. Bonino, M.R. Brunetto – Pisa, Istanbul (Turkey)

Poster

N.57

Poster

Circulating prostaglandin E2: a novel potential prognostic biomarker in patients with hepatocellular carcinoma

F. Pelizzaro, M. P. Kitenge, R. Cardin, B. Penzo, A. Ponzoni, U. Cillo, A. Vitale, G Businello, G. Munari, M. Fassan, F. Farinati – Padua

Poster

N.58

Poster

Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma

C. Campani, M. Capone, F. Liotta, U. Arena, C. Di Bonaventura, S. Colagrande, F. Annunziato, F. Marra Florence

Poster

N.59

Poster

Comparing surgery versus sorafenib in advanced hepatocellular carcinoma: an Italian weighted study

S. Famularo, M. Donadon, F. Cipriani, F. Giuliante, A. Ferrero, S. Molfino, R. Dalla Valle, M. Chiarelli, M. Maestri, E. Jovine, G.L. Grazi, A. Ruzzenente, R. Memeo, M. Crespi, A. Antonucci, D.P. Bernasconi, F. Romano, G. Griseri, L. Aldrighetti, G. Torzilli, F. Trevisani on behalf of ITA.LI.CA. Group and HE.RC.O.LE.S. Group – Milan, Rozzano (Milan), Rome, Turin, Brescia, Parma, Lecco, Pavia, Bologna, Verona, Bari, Monza, Savona

Poster

N.60

Poster

OCA administration reduces lung matrix metalloproteinase activation following hepatic ischemia/reperfusion injury in rats

L.G. Di Pasqua, C. Berardo, G. Palladini, M. Cagna, L. Adorini, P. Richelmi, A. Ferrigno, M. Vairetti-Pavia, San Diego (CA, USA)

Poster

N 61 - 72

N.61

Poster

Treatment of CRKP infections in cirrhotic patients

S. Feldman, S. Di Cola, C. Madge, P. Vassalini, C. Borrazzo, G. Ceccarelli, M. Merli – Rome

Poster

N.62

Poster

Risk factors for post‐banding ulcer bleeding in cirrhotic patients undergoing elective esophageal varices band ligation

G. Tosetti, E. Farina, R. Caccia, E. Degasperi, M. Primignani, P. Lampertico – Milan

Poster

N.63

Poster

The impact of a local antibiotic stewardship program: low rate of spontaneous bacterial peritonitis and bacteriascites sustained by multidrug‐resistant organisms

A. Mantovani, M. Bevilacqua, A. Mazzariol, A. Azzini, E. Tacconelli, D. Sacerdoti, A. Dalbeni-Verona

Poster

N.64

Poster

Analysis of clinical course of portal vein thrombosis in cirrhosis with hepatocellular carcinoma

M. Grasso, A. Vitale, E. Pizzirani, A. Zanetto, E. Gringeri, F. D’Amico, M. Gambato, U. Cillo, P. Burra, M. Senzolo – Padua

Poster

N.65

Poster

Ultrasound guided paracentesis: a study on reproducibility and diagnostic accuracy of a Pocket‐size Ultrasound Device (PUD)

A. Costantino, S. Costa, D. Noviello, E. Farina, M. Vecchi, P. Lampertico, A. Sangiovanni, M. Fraquelli – Milan

Poster

N.66

Poster

Liver Transplantation during the COVID‐19 pandemic: a quantitative model balancing individual patient benefit against population healthcare needs

U. Cillo, A.Vitale, M.L. Volk, A.C. Frigo, P. Feltracco, A. Cattelan, G. Brancaccio, G. Feltrin, P. Angeli, P. Burra, S. Lonardi, S. Trapani, M. Cardillo – Padua, Loma Linda (CA, USA), Rome

Poster

N.67

Poster

Proposal of a new evidence based definition of Early Allograft Failure to identify patients who needs early retransplant and call for a prospective external validation study

A.W. Avolio, G. Moschetta, A. Contegiacomo, L. Miele, L. Teofili, G. Spoletini, S. Agnes, F. Frongillo, G. Bianco, G. Marrone, M. Biolato, A. Grieco, A. Gasbarrini, P. Burra ‐ Rome, Padua

Poster

N.68

Poster

Prevalence and impact on post‐transplant outcome of sarcopenia among patients with cirrhosis on waiting‐list for liver transplantation: preliminary data from an Italian single center experience

F. Invernizzi, M. Iavarone, S. Crespi, B. Antonelli, M. Rusalen, G. Fornoni, G. Carrafiello, G. Rossi, M.F. Donato, P. Lampertico – Milan

Poster

N.69

Poster

Liver transplant candidates and SARS‐CoV‐2 infection: results from an Italian multicenter cohort

G. Perricone, R. Vigano, C. Mazzarelli, G. Travi, L. Pasulo, F. Invernizzi, M.C. Morelli, D. Patrono, S. Di Sandro, P. De Simone, R. Facchetti, D. Angrisani, S. De Nicola, A. Airoldi, M. Vangeli, L.S. Belli – Milan, Bergamo, Bologna, Turin, Modena, Pisa, Monza

Poster

N.70

Poster

COVID‐19 and Solid Organ Transplantation (SOT) in Italy: a web‐survey

F. Galiandro, S. Agnes, F. Giovinazzo, A. Vitale, R. Romagnoli, C. Amarelli, U. Maggiore, P. Burra, U. Boggi, A.W. Avolio ‐ Rome, Padua, Turin, Naples, Parma, Pisa

Poster

N.71

Poster

Liver Transplant in Patient with Breast Cancer Liver Metastasis and Hepatic Failure

V. Giannelli, R. Meniconi, N. Guglielmo, M. Colasanti, C. D’Ambrosio, R. Cianni, E. Cortesi, G.B. Levi Sandri, A.M. Pellicelli, G.M. Ettorre – Rome

Poster

N.72

Poster

Liver stiffness in the early post‐liver transplant phase as a marker of acute allograft rejection

A. Liguori, M. Pascale, M. Biolato, G. Marrone, L. Miele, R. Gaspari, A.W. Avolio, S. Agnes, A. Grieco – Rome

Poster